Pepto-Bismol 262 mg Chewable Tablet
RxNorm 211151
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 211151 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Pepto-Bismol 262 mg Chewable Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
Bismuth subsalicylate 262 mg Chewable Tablet [Pepto-bismol]
(Atom ID: 1165570)
PSNPrescribable
Prescribable Name (PSN):
Pepto-Bismol 262 mg Chewable Tablet
(Atom ID: 6366405)
SYPrescribable
Synonym (SY):
Pepto-bismol 262 mg Chewable Tablet
(Atom ID: 1165572)
SYPrescribable
Synonym (SY):
Pepto-Bismol InstaCool 262 mg Chewable Tablet
(Atom ID: 5083686)
SYPrescribable
Synonym (SY):
Pepto-Bismol To-Go 262 mg Chewable Tablet
(Atom ID: 5069157)
Patient Education
Bismuth Subsalicylate
Bismuth subsalicylate is used to treat diarrhea, heartburn, and upset stomach in adults and children 12 years of age and older. Bismuth subsalicylate is in a class of medications called antidiarrheal agents. It works by decreasing the flow of fluids and electrolytes into the bowel, reduces inflammation within the intestine, and may kill the organisms that can cause diarrhea.
[Learn More]
* Please review the disclaimer below.